Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHTI5X)

Drug Name

N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide Drug Info

Synonyms

N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide; DB07920; N-oxo-2-(4-phenylbenzenesulfonamido)acetamide; N~2~-(biphenyl-4-ylsulfonyl)-N-oxoglycinamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 46937106
TTD Drug ID: DMHTI5X

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Matrix metalloproteinase-12 (MMP-12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[2]
FP-025	DMH1NXO	Asthma	CA23	Phase 1	[3]
PMID29130358-Compound-Figure17(12)	DMML4PA	N. A.	N. A.	Patented	[4]
PMID29130358-Compound-Figure17(10)	DMVA15O	N. A.	N. A.	Patented	[4]
PMID29130358-Compound-Figure17(11)	DMSZA9L	N. A.	N. A.	Patented	[4]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[5]
AZD1236	DML3RSF	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[6]
V85546	DMLFMSY	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[7]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[8]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	DMCNV5J	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Matrix metalloproteinase-12 (MMP-12)	TTXZ0KQ	MMP12_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
3	Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
4	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
5	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
6	Clinical pipeline report, company report or official report of AstraZeneca (2009).
7	Clinical pipeline report, company report or official report of Vernalis.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.